Repatha (Evolocumab): Second PCSK9 Inhibitor Approved by the FDA for Patients with Familial Hypercholesterolemia

Lignende værker

• Praluent (Alirocumab): First PCSK9 Inhibitor Approved by the FDA for Hypercholesterolemia
  af: Raedler, Lisa A.
  Udgivet: (2016)
• FDA Has Approved Evolocumab for Theatment of Familial Hypercholesterolemia in Children
  af: article Editorial
  Udgivet: (2021-12-01)
• FDA Has Approved Evolocumab for Theatment of Familial Hypercholesterolemia in Children
  af: article Editorial
  Udgivet: (2021-12-01)
• Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
  af: Tomlinson, Brian, et al.
  Udgivet: (2021)
• Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
  af: Rosenson, Robert S., et al.
  Udgivet: (2016)